-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The cardiovascular effects of sodium glucose co-transport protein 2 inhibitor Eglie net are not yet clear.
, a research paper on the issue was published in the top medical journal NEJM.
the multi-center, double-blind trial, researchers randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of Eglis or placebo daily.
Researchers aggregated data from two Egler net dose groups for analysis, the main purpose of which was to explore the non-poor effectiveness of Egler net in placebo in the main outcomes of major cardiovascular adverse events (cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke).
the non-adverse effects boundary was 1.3 (the risk of eglie net vs. placebo for major adverse cardiovascular events was higher than the upper limit of the 95.6% confidence interval).
major secondary outcome of the disease is a compound event of death from cardiovascular causes or hospitalization for heart failure.
8,246 patients in the study were randomly grouped, with an average follow-up of 3.5 years.
8238 patients received at least one dose of egle net or placebo treatment, 653 of the 5,493 patients in the egle net group had severe cardiovascular events (11.9%) and 327 of the 2,327 patients in the placebo group Severe cardiovascular events (11.9%) occurred (risk ratio of 0.97; 95.6% confidence interval of 0.85 to 1.11; for non-poor effectiveness, P.lt;0.001).
444 of the 5,499 patients in the Egli net group died of cardiovascular disease or were hospitalized for heart failure (8.1%), and 250 (9.1%) of the 2,747 patients in the placebo group (risk ratio was 0.88; 95.8% CI was 0.75 to 1.03; advantage P was 0.11).
risk ratio of cardiovascular death was 0.92 (95.8% CI 0.77 to 1.11), kidney cause death, and double the risk of death from kidney replacement therapy or serum creatinine levels was 0.81 (95.8% CI was 0.63 to 1.04).
54 patients (2.0 per cent) who received 5mg Egle net treatment and 57 patients (2.1 per cent) who received 15mg Egli net treatment had had their limbs amputated, while 45 patients (1.6 per cent) who received placebo had had amputations.
, it can be seen that in patients with type 2 diabetes and atherosclerosis cardiovascular disease, in terms of major adverse cardiovascular events, the net efficacy of Eglia is no less than a placebo.
.
